Published on
February 25, 2025
- 13:00 GMT
Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package
Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further insights into potential enhanced treatment effects and …
Distribution channels:
Technology
...
